Government pledges to the Global Response fund include: Norway ($1.22 billion) the EC (€1 billion) Japan ($834m) Germany (€525m) France (€500m) Canada (CAD 850m) the UK (£388m) Saudi Arabia ($500m) Switzerland (€378m) Spain (€250m) Australia (AUD 352m) the Netherlands (€192m) and Italy (€100m).On a similar basis, we have not included the total value of the two US government coronavirus emergency supplemental appropriations packages, even where the appropriations are for US government agencies primarily focused on biomedical research and development, but have instead included this funding once commitments have been made by the relevant agencies. Pledged funding that was clearly additional and in scope has been included in our 5 May update, and all pledges will be evaluated for inclusion as more details are made available. Some of the funding in these pledges had already been captured in the tracker, and some is outside its scope (such as for procurement and distribution of newly-developed tools). The totals above also do not include all of the €7.4 billion pledged by world leaders as part of the European Commission-coordinated Coronavirus Global Response fundraising event on. We aim to eventually include this BARDA contract, along with further data, separately on our dashboard to provide context on the additional activities that are vital in getting products to the end-users during a pandemic. For this reason, we have removed BARDA’s $1.2 billion contract with AstraZeneca, which was initially included in our 25 June update but has since been removed. In some cases, funding announcements cover large purchase commitments and manufacturing scale-up costs on top of funding to support late-stage clinical trials. ![]() If you identify any errors or omissions please contact us at Cures Research is working on how to display funding for activities outside our traditional R&D scope. ![]() The dashboards are best viewed in full screen mode, using the buttons at the bottom right of the visualisations.įor a detailed explanation of the scope of this tracking effort and some of the important methodological decisions we’ve made, please see the ‘Why is Policy Cures Research doing this?’ and ‘Types of funding announcements included’ sections at the bottom of the page.Īll of the funding and pipeline data behind this dashboard has been reviewed and validated, but we are relying on publicly available information in a rapidly evolving situation, and as such we acknowledge that our data will never be completely comprehensive. The dashboards below track funding commitments for basic research and product development R&D, and the current status and makeup of the pipeline of new drugs, vaccines and diagnostics, allowing users to identify the key financial and scientific contributors to the global fight against COVID-19. Policy Cures Research has developed this tracker to help funders, policy makers, researchers and others understand the evolving landscape of R&D for COVID-19.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |